Search research articles
Contact Us
Filters
Showing results (161-170 of 304) with videos related to
Page
of 31
Sort By:
Epigenetics
|
May 10, 2017
Placental lipoprotein lipase DNA methylation alterations are associated with gestational diabetes and body composition at 5 years of age
Valérie Gagné-Ouellet, Andrée-Anne Houde, Simon-Pierre Guay, et al.
International Journal of Hypertension
|
February 19, 2015
CYP17A1 and Blood Pressure Reactivity to Stress in Adolescence
Mariel Van Woudenberg, Jean Shin, Manon Bernard, et al.
Lancet (London, England)
|
April 3, 2025
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Kausik K Ray, Ena Oru, Robert S Rosenson, et al.
Epigenetics
|
August 27, 2013
Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases
Stephanie-May Ruchat, Andrée-Anne Houde, Grégory Voisin, et al.
Epigenetics
|
October 12, 2013
Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status
Andrée-Anne Houde, Simon-Pierre Guay, Véronique Desgagné, et al.
Journal of Psychiatry & Neuroscience : JPN
|
October 1, 2014
Prenatal exposure to cigarette smoke interacts with OPRM1 to modulate dietary preference for fat
Ken W K Lee, Michal Abrahamowicz, Gabriel T Leonard, et al.
Epigenomics
|
November 21, 2015
LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia
Andrée-Anne Houde, Stephanie-May Ruchat, Catherine Allard, et al.
The American Journal of Cardiology
|
July 26, 2014
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)
Daniel Gaudet, Dean J Kereiakes, James M McKenney, et al.
JAMA Cardiology
|
September 13, 2023
Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
Robert S Rosenson, Lesley J Burgess, Christoph F Ebenbichler, et al.
Journal of the American College of Cardiology
|
December 18, 2020
Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia
Brian B Ghoshhajra, Borek Foldyna, Daniel Gaudet, et al.
Page
of 31
Search research articles
Search
Showing results (161-170 of 304) with videos related to
Sort By:
Page
of 31
Epigenetics
|
May 10, 2017
Placental lipoprotein lipase DNA methylation alterations are associated with gestational diabetes and body composition at 5 years of age
Valérie Gagné-Ouellet, Andrée-Anne Houde, Simon-Pierre Guay, et al.
International Journal of Hypertension
|
February 19, 2015
CYP17A1 and Blood Pressure Reactivity to Stress in Adolescence
Mariel Van Woudenberg, Jean Shin, Manon Bernard, et al.
Lancet (London, England)
|
April 3, 2025
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Kausik K Ray, Ena Oru, Robert S Rosenson, et al.
Epigenetics
|
August 27, 2013
Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases
Stephanie-May Ruchat, Andrée-Anne Houde, Grégory Voisin, et al.
Epigenetics
|
October 12, 2013
Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status
Andrée-Anne Houde, Simon-Pierre Guay, Véronique Desgagné, et al.
Journal of Psychiatry & Neuroscience : JPN
|
October 1, 2014
Prenatal exposure to cigarette smoke interacts with OPRM1 to modulate dietary preference for fat
Ken W K Lee, Michal Abrahamowicz, Gabriel T Leonard, et al.
Epigenomics
|
November 21, 2015
LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia
Andrée-Anne Houde, Stephanie-May Ruchat, Catherine Allard, et al.
The American Journal of Cardiology
|
July 26, 2014
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)
Daniel Gaudet, Dean J Kereiakes, James M McKenney, et al.
JAMA Cardiology
|
September 13, 2023
Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
Robert S Rosenson, Lesley J Burgess, Christoph F Ebenbichler, et al.
Journal of the American College of Cardiology
|
December 18, 2020
Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia
Brian B Ghoshhajra, Borek Foldyna, Daniel Gaudet, et al.
Page
of 31